ALNEV — Neovacs SA Share News
0.000.00%
Last trade - 00:00- €0.01m
- -€0.03m
- €0.16m
Brief: Neovacs Resumption Of Trading
Brief: Neovacs Asks For Trading Suspension Until July 3
Brief: Neovacs FY Net Loss at EUR 14.8 Mln, Expects to Report Results Of Phase IIB Clinical Trial In Lupus In Mid-2018
Brief: Neovacs Raises 1 Million Euros In Private Placement And 3.8 Million Euros By Issue Of Convertible Bonds
Brief: Neovacs Obtains U.S. Patent For Treatment Of Interpheron Alpha Related Conditions
Brief: Neovacs Announces Positive Data Review From Last IDSMB Review Prior To Final Results Of Phase IIb Clinical Trial Of Ifnalpha Kinoid In Lupus
Brief: Neovacs Granted A New Patent From Russian Federation Patent Office (Rospatent)
Brief: Neovacs Announces Positive Results For IFNalpha Kinoid In Type 1 Diabetes
Brief: Neovacs announces free redeemable share warrants for its shareholders
Brief: Neovacs H1 net loss widens to 8.1 million euros
French and Benelux stocks-Factors to watch on Sept 18
France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus
Brief: Neovacs raises EUR 6.0 million in private placement with U.S. biotechnology institutional investors
Brief: Neovacs announces FDA acceptance of new IND to expand Ifnalpha Kinoid clinical development program in dermatomyositis
Brief: Neovacs syas phase IIb trial Ifnalpha Kinoid in Lupus gets positive IDSMB review
Brief: Neovacs announces license agreement for Ifnalpha Kinoid for treatment of lupus in Turkey
Brief: Neovacs completes patient enrollment in phase IIb clinical study of IFNalpha kinoid
Brief: Neovacs to present clinical development update on ifnalpha kinoid in dermatomyosis
Brief: Neovacs FY operating loss widens to 17.3 million euros